1. Scrip
  2. >>Business

Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal

Plus: Bharat To Start Phase III Vaccine Trials Shortly

 
• By Scrip Team

After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.  

AstraZeneca
AstraZeneca's COVID-19 vaccine trial is still halted in the US, but the company is forging ahead with a new antibody therapy deal with the government.

AstraZeneca PLC has signed a deal with the US government worth around $486m for development and supply of its investigational long-acting monoclonal antibody therapy for COVID-19.

The therapy, named AZD7442, is just about to enter large-scale trials as both a preventative against SARS-CoV-2 infection,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip